CD8A and neoplasm: On the other hand, by using their surface CD80/86 molecules, DCs interact with non-apoptotic tumor plasma cells by the CD28 receptor that is upregulated on their surface, promoting a downregulation of proteasome subunit expression and a consequent escape of myeloma plasma cells from CD8+ T cell recognition and killing (10).